Anthropic: Up to $50,000 in Claude Credits for Rare Genetic Disease Research Through AI for Science
Anthropic has launched a grant program within its AI for Science initiative offering up to $50,000 in Claude credits over six months for rare genetic disease research, with applications open until August 2, 2026, aimed at research teams and early-stage biotech companies accelerating the path from diagnosis to treatment.
This article was generated using artificial intelligence from primary sources.
What does the new grant program offer?
Within its AI for Science initiative, Anthropic has launched a program awarding up to $50,000 in Claude credits over six months to teams researching rare genetic diseases — conditions estimated to affect 400 million people today across more than 7,000 known rare diseases.
Track 1 versus Track 2: research versus biotech
Track 1 supports foundational research in partnership with the Monarch Initiative, using the Mondo Disease Ontology and the DisMech library to map diseases and mechanisms. Track 2 targets early-stage biotech companies accelerating the path from genetic diagnosis to treatment — a process that otherwise takes one to two years.
While Track 1 builds scientific infrastructure, Track 2 funds applied drug development closer to market — two complementary approaches to the same problem.
Deadline and existing recipients
Applications close on August 2, 2026. The program builds on existing partners of Anthropic’s AI for Science initiative — Every Cure, the Centre for Population Genomics, and the Violet Research Institute — which already use Claude credits to accelerate their research.
Frequently Asked Questions
- Who can apply for Anthropic's rare disease grant?
- Research teams can apply under Track 1, in partnership with the Monarch Initiative, while early-stage biotech companies can apply under Track 2; the application deadline is August 2, 2026.
- What are Claude credits in this program?
- Claude credits are vouchers for using Anthropic's AI models worth up to $50,000 over six months, intended to accelerate research into rare genetic diseases.
Sources
📬 AI news in your inbox
A daily digest built your way — pick topics, sources and cadence. One-click unsubscribe.